SWISSTO12
19.3.2024 13:01:29 CET | Business Wire | Press release
SWISSto12, one of Europe’s fastest growing aerospace companies and a leading satellite and Radio Frequency product manufacturer, announces its continued global expansion. The company has secured additional production space at its headquarters in Switzerland, increasing the size of its existing site to 5,700m2. In addition, SWISSto12 has welcomed several new Satcom engineering experts to its growing team, which has increased by 25% since the start of 2024 to over 125 employees working across its facilities in Switzerland, Europe and the USA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318493042/en/
HummingSat I-8 Inmarsat (Photo: Business Wire)
SWISSto12 was recently named as one of the world’s “10 Hottest Satellite Companies.” This industry recognition follows the company’s announcement in Q4 2023 of securing over €200 million in customer orders for Radio Frequency subsystems and HummingSat satellites, including from leading satellite operators Inmarsat (Viasat) and Intelsat.
Industry veteran Peter Bach Andersen started working with the SWISSto12 team in November 2023 along with colleagues based out of Denmark. Peter Bach Anderson previously spent eleven years at Cobham Satcom in Kongens Lyngby, Denmark where he led the development of new RF, Microwave and Antenna technologies.
Peter Bach Andersen, Principal SatCom Systems Engineer, said, “Denmark is a world-renowned hub for aerospace and SatCom engineering. SWISSto12 has started to partner with a number of significant experts in the local area across Radio Frequency engineering and development roles and I look forward to collaborating with Swissto12 on their exciting Satcom projects.”
Emile de Rijk, CEO of SWISSto12 said, “SWISSto12 is continuing to scale in order to meet exceptional customer demand for our Radio Frequency subsystems and HummingSat – the first commercial GEO SmallSat. In Denmark, we have access to one of Europe’s leading aerospace and SatCom engineering talent pools. The addition of new production space and a new additional cleanroom to our Renens headquarters is further accelerating our mission to industrialise and scale our product lines and production capabilities.”
SWISSto12 will be exhibiting at Satellite 2024 in Washington DC 18 -21 March 2024 at Booth #1408. On 19 March, SWISSto12 CEO Emile de Rijk will be speaking at Satellite 2024 on “Assuring Quality-of-Service at Sea: Maritime Satellite Connectivity.”
About SWISSto12
SWISSto12 is a leading manufacturer of advanced satellite RF products, payloads and systems, including the HummingSat: a small yet powerful geostationary telecommunications satellite developed in collaboration with the European Space Agency (ESA) through its public-private-partnership program. The company’s RF products benefit from unique and patented 3D-printing technologies and associated Radio Frequency (RF) product designs that deliver lightweight, compact, highly performing, and competitive RF functionality. Besides its space portfolio, the company is also active in telecommunications and surveillance applications for the aeronautic industry. SWISSto12 has developed commercially with success in Europe and in the USA, and is amongst the fastest growing aerospace companies in Europe. SWISSto12 spun off in 2011 from the Swiss Federal Institute of Technology in Lausanne (EPFL), is privately owned and backed by prominent Swiss and European Investors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318493042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom